Structural Determination of Three Different Series of Compounds as Hsp90 Inhibitors Using 3D-QSAR Modeling, Molecular Docking and Molecular Dynamics Methods by Liu, Jianling et al.
Int. J. Mol. Sci. 2011, 12, 946-970; doi:10.3390/ijms12020946 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Article 
Structural Determination of Three Different Series of 
Compounds as Hsp90 Inhibitors Using 3D-QSAR Modeling, 
Molecular Docking and Molecular Dynamics Methods  
Jianling Liu 
1, Fangfang Wang 
1, Zhi Ma 
2, Xia Wang 
2 and Yonghua Wang 
2,* 
1  College of Life Sciences, Northwest University, Xi’an, Shaanxi 710069, China;  
E-Mails: ljl2003ljl@126.com (J.L.); yu100288@163.com (F.W.) 
2  Center of Bioinformatics, Northwest A&F University, Yangling, Shaanxi 712100, China;  
E-Mails: mshappy@126.com (Z.M.); fishery18@163.com (X.W.) 
*  Author to whom correspondence should be addressed; E-Mail: yonhuawang@gmail.com;  
Tel.: +86-29-87092262; Fax: +86-29-87092262. 
Received: 11 November 2010; in revised form: 11 January 2011 / Accepted: 25 January 2011 /  
Published: 30 January 2011 
 
Abstract: Hsp90 is involved in correcting, folding, maturation and activation of a diverse 
array of client proteins; it has also been implicated in the treatment of cancer in recent 
years. In this work, comparative molecular field analysis (CoMFA), comparative molecular 
similarity indices analysis (CoMSIA), molecular docking and molecular dynamics were 
performed on three different series of Hsp90 inhibitors to build 3D-QSAR models, which 
were  based  on  the  ligand-based  or  receptor-based  methods.  The  optimum  3D-QSAR 
models exhibited reasonable statistical characteristics with averaging internal q
2 > 0.60 and 
external r
2
pred > 0.66 for Benzamide tetrahydro-4H-carbazol-4-one analogs (BT), AT13387 
derivatives  (AT)  and  Dihydroxylphenyl  amides  (DA).  The  results  revealed  that  steric 
effects contributed the most to the BT model, whereas H-bonding was more important to 
AT, and electrostatic, hydrophobic, H-bond donor almost contributed equally to the DA 
model.  The  docking  analysis  showed  that  Asp93,  Tyr139  and  Thr184  in  Hsp90  are 
important for the three series of inhibitors. Molecular dynamics simulation (MD) further 
indicated  that  the  conformation  derived  from  docking  is  basically  consistent  with  the 
average structure extracted from MD simulation. These results not only lead to a better 
understanding of interactions between these inhibitors and Hsp90 receptor but also provide 
useful information for the design of new inhibitors with a specific activity. 
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1. Introduction 
Hsp90  belongs  to  a  family  of  proteins  called  molecular  chaperones  that  are  responsible  for 
maintaining the appropriate folding and three-dimensional conformation of proteins in the cell and are 
critical  for  controlling  the  balance  between  the  synthesis  and  degradation  of  many  proteins. 
Furthermore, they have also been shown to play an important role not only in the stress response but 
also in regulating many critical cellular functions, such as cell proliferation and apoptosis [1–3]. More 
recently, Hsp90 has emerged as a very important and validated target in several diseases including 
cancer, neurodegeneration, viral, fungal, and microbial infection [4–14]. Therefore the development of 
Hsp90 inhibitors has become an urgent field in both theoretical and practical fields, in view of the 
urgency for improving cancer treatment in recent years. 
Hsp90 exists as two isoforms: Hsp90α and Hsp90β [15]. In this study, we adopted Hsp90α as the 
target  as  Hsp90α  is  an  inducible  form  overexpressed  in  cancer  cells.  Hsp90  consists  of  a  highly 
conserved N-terminal domain, a charged linker, and a highly conserved C-terminal region, the charged 
linker is not important for Hsp90 function, and the inhibitors of Hsp90 mainly bind to the  N-and  
C-terminal regions [16–18]. These inhibitors first act on Hsp90, then disrupt client proteins folding and 
degradation via the ubiquitin-proteasome pathway. Since Hsp90 client proteins are signaling proteins 
implicated  in  survival/proliferation,  including  protein  kinases,  antiapoptotic  proteins  and  
transcription factors, its inhibition has the potential to simultaneously interfere with multiple signaling 
pathways [16–18]; meanwhile, these proteins are important for tumor cell survival. The N-terminal 
domain  binds  the  natural  products  geldanamycin  (GDA),  radicicol  and  their  derivatives,  which 
modulate at least two different conformational states. Novobiocin binds to the C-terminal nucleotide 
binding site and inhibits Hsp90 function. In this work, we mainly focus on uncovering the interaction 
mechanism of inhibitors in the N-terminal site of the protein.  
The  first  Hsp90  inhibitor  drug  is  geldanamycin,  a  natural  product  isolated  from  Streptomyces 
hygroscopicus  [19].  Although  geldanamycin  displays  high  potency  in  cytotoxicity  assays,  it  also 
shows hepatotoxicity  in  preclinical  trials  [20].  Interestingly,  the  geldanamycin  analogue  17AAG  
(17-allylamino-17-demethoxy-geldanamycin)  possesses  all  the  Hsp90-related  characteristics  of 
geldanamycin  but  with  lower  toxicity  [19,21,22].  Although  less  hepatotoxic  than  geldanamycin,  
17-AAG  is  poorly  soluble,  difficult  to  formulate  and  undergoes  extensive  metabolism  leading  to  
non-target-based  effects  [21].  Another  natural  Hsp90  inhibitor  is  radicicol  (RD),  which  has  high 
binding  affinity,  but  limited  in  vivo  stability.  Besides  these  natural  compounds,  some  synthesized 
inhibitors have also shown promising effects on Hsp90, for example, purine-based inhibitors [23,24], 
the Pyrazole-isoxazole analogues, Novobiocin and coumarin scaffold analogues, such as 4TCNA [25]. 
The  deficiency  of  natural  compounds  led  to  significant  efforts  to  identify  novel  small  molecule 
inhibitors  of  Hsp90  which  had  more  potent  inhibitory  activity  and  could  ideally  be  fitted  for 
combination therapies for cancer. To date, a number of Hsp90 inhibitors have been reported [26–28]. 
More  recently,  the  3D-QSAR  (3  dimensional-quantitative  structure-activity  relationship)  including Int. J. Mol. Sci. 2011, 12                       
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CoMFA, CoMSIA and 3D-pharmacophore and docking methods were employed to investigate PU3 
analogues  [29,30],  which  provided  useful  models  for  designing  the  Hsp90  targeted  inhibitors.  In 
addition, another work has described an integrated 3D-QSAR model using pharmacophore modeling 
and  docking  approaches  applied  on  a  dataset  of  72  Hsp90  adenine  inhibitors  [31].  The  results  
found  a  set  of  pharmacophoric  features,  i.e.,  one  H-bond  donor,  one  H-bond  acceptor,  one 
hydrophobic_aromatic, and two hydrophobic_aliphatic features, which might be of import to develop 
inhibitors as anti-cancer agents [31]. At the same time, some other series  of compounds, such as 
Benzamide  tetrahydro-4H-carbazol-4-one  analogs  (BT)  [32],  AT13387  derivatives  (AT)  [33]  and 
Dihydroxylphenyl  amides  (DA)  [34],  have  been  developed  as  further  potent  Hsp90  inhibitors.  In 
these literatures,  the  authors  only  synthesized  and  evaluated  the  inhibitors;  to  date,  there  are  no  
three-dimensional quantitative relationship (3D-QSAR) studies of the ligands reported. Moreover, no 
comprehensive feature for the ligand-receptor interactions, such as the hydrophobic contact between the 
key  amino  acid  residues  has  been  demonstrated.  Therefore,  in  order  to  investigate  the  binding 
mechanism and the properties of these inhibitors, we have studied the quantitative structure—activity 
relationships  of  these  three  classes  of  Hsp90  inhibitors.  In  this  work,  we  used  the  comparative 
molecular  field  analysis  (CoMFA)  [35]  and  comparative  molecular  similarity  indices  analysis 
(CoMSIA)  methods  [36]  to  produce  3D-QSAR  models  with  the  ligand-based  and  receptor-based 
approaches for three different classes of Hsp90 inhibitors. Ligand-based 3D-QSAR approaches were 
reported to be effective for understanding the structure—activity relationships [37]. While the more 
reliable receptor-based 3D-QSAR methods were also employed to demonstrate the physical-chemical 
principles of the interactions between inhibitors and Hsp90. Moreover, the contour map generated 
from the CoMFA and CoMSIA models can further illustrate the observed variation in activity for the 
given structural differences in these inhibitors. In addition, molecular dynamics was performed to 
better understand the probable binding modes of these inhibitors. The developed models can, not only 
be used to predict the activities of new designed inhibitors, but also to provide useful information for 
modification in the design of new potential inhibitors. 
2. Material and Methods 
2.1. Data Sets and Biological Activity 
The 89 compounds involved in this study were taken from [32–34]. Those molecules that did not 
have the specified inhibitory activity and did not share a common scaffold with the other molecules 
were discarded. Inhibitory concentrations Kd (μM) and IC50 (μM) of the molecules were converted into 
corresponding  inhibitory  activity  pKd  (−logKd)  and  pIC50  (−logIC50)  values,  which  were  used  as 
dependent  variables  in  the  3D-QSAR  analysis. The  total  set  for  each  group  was  divided  into  the 
training set and the test set. The test set was selected by considering that the test compounds represent 
structural diversity and a range of biological activities similar to that of the training set. In addition, the 
training set was used to generate 3D-QSAR models, while the test set was employed to validate the 
quality of the models. All the chemicals and activities are presented in Tables S1–S3. 
All molecular modeling was performed using SYBYL package (Tripos Associates, St. Louis, MO, 
U.S.). 3D structures of all molecules were constructed using the Sketch Molecule function in Sybyl Int. J. Mol. Sci. 2011, 12                       
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software. Gasteiger-Hü ckel charges were employed to calculate the partial atomic charges. Energy 
minimization was performed by using the Tripos force field [38] with the Powell conjugate gradient 
minimization algorithm and a convergence criterion of 0.05 kcal/mol· Å. 
2.2. Conformational Sampling and Alignment  
In the 3D-QSAR studies, in order to obtain valid and reliable models, molecular alignment was 
employed. In this study, two alignment rules were employed; one is ligand-based alignment. In this 
method, a molecule of each class that has the most potent inhibitory activity (compounds 17, 24, 19, 
respectively) was chosen as template molecule to align with the remaining training and test compounds 
by using the Database Align function in SYBYL. The common substructure of the compounds is 
shown in bold in Figure 1 and the aligned compounds are depicted in Figure 2. The other approach is 
the receptor-based alignment, in which the aligned results are further applied to QSAR analysis. The 
receptor-based alignment is shown in Figure 3. 
Figure 1. Skeletons for benzamide tetrahydro-4H-carbazol-4-one analogs (A); AT13387 
Derivatives (B) and dihydroxylphenyl amides (C). 
(A) 
 
(B) 
 
(C) 
 
Figure  2.  Ligand-based  alignment.  (A)  Compound  17  was  used  as  a  template  for 
alignment; (B) Compound 24 was used as a template for alignment; (C) Compound 19 was 
employed as a template for alignment. C is colored in white; H is colored in cyan; O is 
colored in red; N is colored in blue; S is colored in yellow. 
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Figure  3. Receptor-based alignment. (A) Compound 17 was selected as a template for 
alignment; (B) Compound 24 was used as a template for alignment; (C) Compound 19 was 
employed as a template for alignment. Alignment of these compounds was further used for 
3D-QSAR model generation. 
 
2.3. 3D-QSAR Analysis 
CoMFA and CoMSIA studies were performed based on the molecular alignment as described above in 
order to build predictive 3D-QSAR models. CoMFA calculates steric and electrostatic properties, whereas 
CoMSIA calculates similarity indices in the space surrounding each of the molecules in the dataset. 
The aligned molecules were placed in a 3D grid box of 2.0 Å such that the entire set was included 
in  the  simulation  box.  The  CoMFA  descriptors,  steric  field  and  electrostatic  fields  with  a 
distance-dependent dielectric at each grid point were calculated using a sp3 carbon atom probe with a 
vander Waals radius of 1.52 Å and a charge of +1.0 using default settings in SYBYL. The CoMFA 
fields  generated  automatically  were  scaled  by  the  CoMFA-STD  method  with  default  energy 
of 30 kcal/mol. 
In  addition  to  steric  and  electrostatic  fields,  hydrophobic,  hydrogen-bond  donor  and  acceptor 
descriptors were calculated in CoMSIA models. CoMSIA similarity index descriptors were derived 
using the same lattice box as that used in  the CoMFA calculations. All the five physicochemical 
descriptors were calculated using the standard settings that probe with charge +1, radius 1 Å and 
hydrophobicity +1, hydrogen-bond donating +1, hydrogen-bond accepting +1, attenuation factor α of 
0.3 and grid spacing 2 Å. CoMSIA similarity indices (AF) for a molecule j with atoms i at a grid point 
q are calculated by Equation (1) as follows: 
 
(1) 
Five  physicochemical  properties  k  (steric,  electrostatic,  hydrophobic,  hydrogen  bond  donor,  and 
hydrogen bond acceptor) were evaluated using the common sp
3 carbon probe atom. Wik is the actual 
value of physicochemical property k of atom i, and Wprobe,k is the value of the probe atom. α is the 
attenuation factor and the default value of 0.3 was used. A Gaussian type distance dependence was used 
between the grid point q and each atom i of the molecule. This can avoid singularities at the atomic 
positions and the dramatic changes of potential energy due to grids in the proximity of the surface [39]. 
The CoMFA/CoMSIA fields combined with observed biological activities (pIC50) were included in 
a  molecular  spreadsheet  and  partial  least  square  (PLS)  methods  [40]  were  applied  to  generate  
2 F,K probe, ()
r q
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
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3D-QSAR  models.  The  cross-validation  analysis  was  performed  using  the  leave-one-out  (LOO) 
method. The cross-validated r
2 which was used to generate the optimum number of components and 
lowest standard error of prediction were taken. Then the optimum number of components obtained 
from the cross-validation analysis was used to calculate the conventional r
2. The predictive ability of 
the 3D-QSAR model was determined using the compounds which were not included in the training set. 
The  predictive  correlation  coefficient  rpred
2,  based  on  the  test  set  molecules,  was  calculated using 
Equation (2):  
  (2) 
where, SD is the sum of the squared deviations between the biological activities of the test set and 
mean activities of the training set molecules and PRESS is the sum of squared deviation between 
predicted and actual activities of the test set compounds. 
2.4. Molecular Docking 
Molecular docking is an application wherein molecular modeling techniques are used to predict 
how  a  protein  (enzyme)  interacts  with  small  molecules  (ligands)  [41].  Molecular  docking  was 
performed to study the binding modes for the allosteric site of Hsp90 protein with its ligands and to 
develop docking-based 3D-QSAR models. All the parameters were set as the default values in the 
whole process. The crystal structures of Hsp90 have been obtained from RCSB protein data bank [42] 
(3D0B,  2XJG  and  3K97).  During  the  procedure,  two  parameters,  i.e., protomol_bloat  and 
protomol_threshold, which can determine how far from a potential ligand the site should extend and 
how deep into the protein, the atomic probes used to define the protomol can penetrate, are specified 
default values. Finally, each conformer of all 89 inhibitors in three different groups, was docked into 
the binding site 10 times. During the process, water molecules and the inhibitors were removed and 
hydrogens  were  added  to  the  system.  The  putative  poses  of  molecules  were  scored  using  the 
Hammerhead scoring function [43], which also served as an objective function for local optimization 
of poses. On the other hand, the ligands (i.e., substrates) were regarded as being flexible, while the 
enzyme  was  regarded  as  rigid.  Finally,  the  highest-ranking  conformers/poses,  according  to  each 
scoring function, were aligned together for CoMFA and CoMSIA modeling. 
Before docking analysis, a redocking process was performed to verify that the docking parameters 
specified in the input file for docking method were reasonable, and able to recover a known complex’s 
structure and interactions. The root-mean-square deviation (RMSD) values are between 0.7 and 1.6 Å for 
the 10 top-ranked docking poses for BT, between 0.6 and 1.9 for AT and between 0.08 and 0.6 for DA. 
2.5. Molecular Dynamics Simulations 
All MD simulations were performed with the GROMACS program package [44], employing the 
GROMOS96 force field [45]. For MD simulations, the three models (BT, AT and DA) used NPT 
ensemble at 300 K with periodic boundary conditions, and the temperature was kept constant by a 
Berendsen  thermostat;  the  values  of  the  isothermal  compressibility  were  set  to  4.5  ×   10
−5  bar
−1. 
Van der Waals interactions and cut-off distances for the calculation of Coulomb were 1.4 and 1.0 nm, 
respectively. The particle mesh Ewald method [46] was used to calculate electrostatic interactions. 
2
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For this simulation, each system applied a cubic periodic box with a side length of 70.55 Å, 66.81 Å 
and 74.77 Å, respectively. Between the protein and the box walls the minimum distance was set to 
more than 8 Å. The net charge of the protein was neutralized by 8 Na
+, 11 Na
+ and 8 Na
+ for BT, AT, 
DA series of Hsp90 inhibitors. The extended simple point charge (SPCE) water model [47] was used 
to fill the remaining box volume. The total number of the atoms in each simulation system was 30,209, 
36,696, 25,048 including complex and waters. 
In the simulation process, the whole system was first minimized by using 5000 steepest descent 
steps.  This  was  followed  by  a  200  ps  MD  run  to  equilibrate  the  water  molecules,  protein  and 
counterions.  The  simulation  was  run  with  LINCS  algorithms  [48]  on  hydrogen  atoms  and  then 
continued for 5 ns by using 2 fs time step, where the coordinates were saved every 5 ps for analysis. 
3. Results and Discussion  
3.1. CoMFA and CoMSIA Statistical Results 
An effective 3D-QSAR model is generated by considering a number of statistical parameters, such 
as the cross-validated correlation coefficient (r
2
cv), non-cross-validated correlation coefficient (r
2
ncv), 
standard error estimate (SEE) and F-statistic values (F). The CoMFA and CoMSIA models are built 
after  model  development  and  validation  based  on  internal  predictions  of  the  training  set  and  the 
external predictions of the test set. 
For CoMFA analysis, a cross-validated partial least-square (PLS) analysis is performed using the 
leave-one-out option which produces the cross-validated correlation coefficient (q
2) values and the 
optimal  number  of  components.  Generally,  in  3D-QSAR  studies,  a  cross-validated  regression 
coefficient q
2 being higher than 0.5 can be considered as statistical proof with high predictability [49]. 
Then, using the optimal number of components found earlier, the non-cross-validated PLS analysis is 
performed to produce a non-cross-validated correlation coefficient (r
2
ncv), a standard error estimate 
(SEE) and F-statistic values which can combine to evaluate the models. 
For CoMSIA analysis, five descriptors (steric, electrostatic, hydrophobic, hydrogen-bond-donor and 
hydrogen-bond-acceptor)  are  considered.  However,  some  previous  work  has  found  that  the  five 
descriptor fields are not totally independent of each other and such dependencies of individual fields 
might decrease the statistical significance of the models [50,51]. Therefore, in this work all 31 possible 
descriptors’ combinations for each group are calculated to provide the optimal models. The statistical 
results are summarized in Table 1. 
In both the CoMFA and CoMSIA analysis, the models produced from the ligand-based alignment 
are better than the receptor-based alignment. So, we mainly discuss the ligand-based models in this 
study. Other than the optimum results listed in this paper, the others are shown in the supporting 
information (Tables S4–S9). 
3.2. Validation of the 3D QSAR Models 
A predictive correlation coefficient r
2
pred is used to determine the stability and predictive abilities of 
the obtained models from the test sets which were not used to construct the models. The resultant 
optimum models exhibit agreeable statistical results for three classes and are shown in Table 1. The Int. J. Mol. Sci. 2011, 12                       
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correlation between the CoMFA and CoMSIA predicted activities and the experimental activities of 
the test set compounds are shown in Figure 4. The test results indicate that the CoMFA and CoMSIA 
models are reliable. 
Table 1. The best results of the CoMFA and CoMSIA analyses for the training and test 
set compounds.  
Parameters 
Benzamide tetrahydro-4H 
-carbazol-4-one analogs 
AT13387 
Dihydroxylphenyl 
amides 
CoMFA  CoMSIA  CoMSIA 
R
2
cv  0.482  0.715  0.645 
R
2
ncv  0.903  0.892  0.858 
SEE  0.22  0.304  0.478 
F  78.818  86.941  60.608 
R
2
pred  0.5747  0.7013  0.7177 
SEP  0.507  0.494  0.757 
Nc  2  2  2 
Field Contribution 
S  0.825  0.179  0.153 
E  0.175  0.322  0.285 
H  -  -  0.29 
D  -  0.499  0.273 
A  -  -  - 
R
2
cv = Cross-validated correlation coefficient after the leave-one-out procedure; R
2
ncv = Non-
cross-validated  correlation  coefficient;  SEE = Standard  error  of  estimate;  F = Ratio  of  R
2
ncv 
explained to unexplained = R
2
ncv/(1 − R
2
ncv); R
2
pred = Predicted correlation coefficient for the 
test set of compounds; SEP = Standard error of prediction; Nc = Optimal number of principal 
components;  S = Steric;  E = Electrostatic;  H = Hydrophobic;  D = Hydrogen-bond-donor; 
A = Hydrogen-bond-acceptor. 
Figure 4. Plot of the predicted pIC50 versus the experimental pIC50 values for the models. 
(A)  COMFA  model  of  benzamide  tetrahydro-4H-carbazol-4-one  analogs;  (B)  CoMSIA 
model of AT13387 Derivatives; (C) CoMSIA model of dihydroxylphenyl amides.  
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3.2.1. BT 
Eight compounds (shown in Table S1) out of the total twenty eight Hsp90 inhibitors were used as the 
test set and the remaining compounds were used as the training set. The statistical results of the optimal 
model are shown in Table 1. The optimal CoMFA model gives a q
2 of 0.428 for two components and 
F of 78.818, with a SEE of 0.22 and shows good predictive ability. However, the CoMSIA model shows 
poor internal predictions (r
2
cv = 0.408) relative to the CoMFA model using steric and electrostatic fields. 
Meanwhile, an incorporation of the hydrophobic field makes the models perform poorer, and attempting 
to use all possible field combinations also could not improve the model performance. All this suggests 
that the CoMFA model is superior to the CoMSIA model for this class of Hsp90 inhibitors. 
For the results of CoMFA model, the r
2
pred is 0.2769 before omitting compound 11; after discarding 
it, the predicted value increased to 0.5747, indicating compound 11 is the outlier. The outlier status of 
compound 11 can stem from its low activity (Kd = 2.9), compared to its counterpart, compound 12. 
Furthermore, it has a higher residue between the observed and predicted biological activity which 
further confirms the robustness and statistical confidence of the derived model. 
3.2.2. AT 
The statistical parameters of the optimal model, for AT, are summarized in Table 1. The highest q
2 
of 0.715 is obtained with two components. F = 86.941, SEE = 0.304, r
2
pred = 0.7013 and SEP = 0.494 
for the model derived from the combinations of SED descriptors. At the same time, the model derived 
from  the  combinations  of  SEHDA  also  shows  comparable  predictions.  However,  incorporation  of 
hydrophobic and hydrogen-bond-acceptor fields to SED, led to no notable improvement in statistical 
features (q
2 = 0.728, SEE = 0.268, F = 115.04, r
2
pred = 0.5398). So, the model shown in Table 1was 
selected as the optimum model for further analysis, showing reasonable statistical features. On the 
other hand, the CoMFA model gives a q
2 of 0.604 for two components, r
2
pred of 0.7272. Overall, the 
performance of the CoMSIA model is superior to that of the CoMFA one. The decrease of contribution 
of  steric  field  in  the  CoMSIA  model  (shown  in  Table  1)  can  be  explained  by  introducing  a 
hydrophobic field in the CoMSIA model, and also by the fact that in some cases, the steric field is 
correlated to some extent with hydrophobic field [52].  
Compound 6 in the CoMFA and CoMSIA models was treated as an outlier. On inclusion of this 
compound, the model showed poor predictive ability with r
2
pred of 0.2225. Omission of compound 6 
resulted in an increased r
2
pred value of 0.7272 for CoMFA model. There are several reasons that may 
account for outliers, including unique structural differences, different binding conformations, and a 
higher residual between the observed and predicted biological activity of an inhibitor. Compound 6 
was  very  similar  in  structure  to  compound  5;  the  only  difference  being  that  the  substituent  of 
compound 6 is a cyclopropyl, which is also the only inhibitor with cyclic substituent in this position, 
and might account for its outlier status. 
3.2.3. DA 
In this model, the data set is divided into a training set of 23 and a test set of 6 molecules. The most 
active compound, 19, was selected as a template to sketch the rest of the molecules. Figure 2C shows Int. J. Mol. Sci. 2011, 12                       
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the aligned molecules which are further used to generate the CoMFA and CoMSIA columns. The 
CoMSIA results are shown in Table 1. The CoMFA and CoMSIA statistical data show q
2 of 0.401 for 
CoMFA, and 0.645 for the CoMSIA models, respectively, indicating that the CoMSIA model has 
better internal predictive ability than the CoMFA model. 
In the CoMSIA model, PLS analysis of this group of Hsp90 inhibitors of the training set showed  
cross-validated  q
2  of  0.645  using  two  principal  components,  and  the  non  cross-validated  r
2 value 
was 0.858, with a SEE, SEP and F value of 0.478, 0.757 and 60.608, respectively. The CoMFA model 
exhibits a q
2 of 0.401 with two compounds, with the non-cross-validated r
2 of 0.724, F = 26.192 and 
SEE  of  0.668.  Table  1  shows  that  the  steric  field  and  electrostatic  field  have  an  almost  similar 
influence on producing the CoMFA model. This 3D-QSAR model was further validated using the 
external test set. Both the CoMFA and CoMSIA models gave r
2
pred of 0.6913 and 0.7177, respectively. 
The values suggest that all these models have good generalization ability in the test set. 
3.3. 3D-QSAR Contour Maps  
CoMFA, and CoMSIA contour maps were generated to visualize the information of the derived  
3D-QSAR  model  by  plotting  the  coefficients  from  CoMFA  and  CoMSIA  QSAR  models,  which 
represent the lattice points and the difference in the field values at lattice point. Briefly, the contour 
maps  indicate  regions  in  3D  space  around  the  molecules  where  changes  in  the  particular 
physicochemical properties are predicted to increase or decrease potency. To aid in visualization, the 
most active compounds are shown with the contour maps. 
3.3.1. BT  
The CoMFA contour plots of steric and electrostatic interactions are shown in Figure 5. Figure 5A 
shows the steric contour map with the highly active inhibitor 17 (pKd = 6.6021) as a reference. A large 
region of green contour near Region B (shown in Figure 6A) indicates that steric bulk is favored there. 
This  is  consistent  with  the  reported  experimental  results  that  compounds  7,  8,  9,  10  with  bulky 
substituent were more active than compounds 1–6 with small substituents [32]. A small yellow contour 
is close to the N atom of Region A, which indicates that bulky groups at this position would decrease 
the potency. Several yellow contours are observed outside the Region B and around the green contour, 
which strongly delimits the sideward relocatability. For example, compounds 16, 17, 18 with high 
inhibitory activity can be explained as they have moderate substituents at the R1 position that cannot 
reach the yellow contour area. However, molecules 19, 20, 22, and 24 show complete incorporation of 
extended  side  chain  into  the  yellow  region,  apparently  responsible  for  their  lower  potency.  This 
indicates that the optimal length of substituent at R1 position would enhance the activity of these 
compounds (10 and 17). 
The  electrostatic  contour  map  is  shown  in  Figure  5B.  Two  blue  polyhedra  encompassing  the 
benzamide indicate positively charged groups which are beneficial to the activity. Positively charged 
propylene at Region B of compound 17 leads to its high activity (pKd = 6.6021), while the negatively 
charged bromo, cyano and methoxy group at the same position of compounds 3, 4, 5 respectively show 
inactivity. Three red contours at the opposite sites of the blue polyhedra indicate that electronegative 
groups are tolerated at this position. Both of the electropositive favored and electronegative contours Int. J. Mol. Sci. 2011, 12                       
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emerge at the same region which indicates that a balance of these properties among the groups present 
at this region is required for optimum binding. 
Figure 5. CoMFA StDev*Coeff contour plots for benzamide tetrahydro-4H-carbazol-4-one 
analogs in combination with compound 17. (A) The green (sterically favorable) and yellow 
(sterically unfavorable) contours represent 80% and 20% level contributions, respectively; 
(B) The blue (electropositive charge favorable) and red (electronegative charge favorable) 
contours represent 70% and 30% level contributions, respectively. 
 
Figure 6. The most active molecule showing different regions which are used in contour 
analysis.  (A)  Compound  17  in  the  group  of  benzamide  tetrahydro-4H-carbazol-4-one 
analogs; (B) Compound 24 in the class of AT13387 Derivatives; (C) Compound 19 in the 
series of dihydroxylphenyl amides.  
 
3.3.2. AT 
The contour maps of CoMSIA (steric, electrostatic, hydrogen-bond-donor) are represented by color 
codes shown in Figure 7. To aid in visualization, the highly active inhibitor 24 was overlaid in the maps. 
Figure 7A shows the CoMSIA steric field. One medium sized of green contour near the 5’ position 
(shown in Figure 6B) of benzamide ring indicates that bulk subtituents are favorable in this region. 
Another green contour region, around the 5-position of isoindoline, suggests that a bulky substituent is 
preferred in this position to produce higher inhibitory activity. The activity of compound 12 decreased 
after the -F substituent on that position was replaced with a less bulky group, such as compound  Int. J. Mol. Sci. 2011, 12                       
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10 (-Cl). The yellow contour near the 3-position of benzamide ring indicates the need for a small 
substituent  in  this  area  to  enhance  the  biological  activity.  This  is  consistent  with  the  reported 
experimental results of one compound which is not listed in this study because it binds very weakly [33].  
The graphical interpretation of the electrostatic interaction in the CoMSIA model is represented in 
Figure 7B. The red contour near the 5’ position of isoindoline indicates electronegative groups are 
beneﬁcial to the activity. This is in accord with compounds 23, 24, 25 and compounds 17, 31, 32, the 
activity of the former is larger than that of the latter, because the former possesses a more electronegative 
atom  (-O)  than  the  latter  (-C)  at  this  position.  Another  red  contour  appears  at  the  
2-position of benzamide, showing that an electronegative group here is important for inhibitory activity. 
The blue contour seperate from the main contour map indicates that electropositive groups which can 
extend  to  this  region  add  to  its  activity.  The  large  blue  contour  around  the  isoindoline  suggests 
electropositive groups are preferred at this position. The electronegative oxygen atom at 4-position of 
benzamide embedded in the blue contour, suggests that it is unfavorable for  the inhibitory activity. 
Therefore, we suggest replacing the hydroxyl with an electropositive group, which may be beneficial to 
the activity. 
Figure  7C  indicates  areas  where  hydrogen-bond-donors  in  the  ligand  promote  or  decrease  the 
inhibitory  activity.  Two  purple  contours  either  side  of  the  R4  substituent  suggest  that  
H-bond donor groups are disfavored here; this can be explained by compound 29 with two -NH in this 
region  exhibiting  lower  activity  (pKd = 8.8861)  than  compound  24.  However,  the  most  potent 
compound 24 also has one H-bond donor group -NH in this area suggesting that there is room for 
modification at this position considering the effect of H-bond donor. The large polyhedra around the 
benzamide implies that H-bond donor groups could have a positive effect on the inhibitory activity. In 
addition, it has H atom at the 3-position. From the contour, we can conclude that maybe it is better for 
the inhibitory activity if the H atom is transformed to other H-bond donor groups.  
Figure 7. CoMSIA StDev*Coeff contour plots for AT13387 Derivatives in combinition 
with compound 24. (A) The green (sterically favorable) and yellow (sterically unfavorable) 
contours  represent  80%  and  20%  level  contributions,  respectively;  (B)  The  blue 
(electropositive  charge  favorable)  and  red  (electronegative  charge  favorable)  contours 
represent 70% and 30% level contributions, respectively; (C) The cyan (hydrogen-bond-
donor favorable) and purple (hydrogen-bond-donor unfavorable) contours represent 70% 
and 30% level contributions, respectively. 
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Figure 7. Cont. 
 
3.3.3. DA 
The CoMSIA contour maps of steric, electrostatic, hydrophobic and hydrogen-bond-donor fields 
are shown in Figure 8. The most potent compound, 19, is displayed as a reference.  
Figure  8.  CoMSIA  StDev*Coeff  contour  plots  for  Dihydroxylphenyl  amides  in 
combination with compound 19. (A) The green (sterically favorable) and yellow (sterically 
unfavorable) contours represent 90% and 10% level contributions, respectively; (B) The 
blue (electropositive charge favorable) and red (electronegative charge favorable) contours 
represent 80% and 20% level contributions, respectively; (C) The yellow (hydrophobic 
favorable) and white (hydrophobic unfavorable) contours represent 80% and 20% level 
contributions,  respectively;  (D)  The  cyan  (hydrogen-bond-donor  favorable)  and 
purple (hydrogen-bond-donor  unfavorable)  contours  represent  80%  and  20%  level 
contributions, respectively. 
 Int. J. Mol. Sci. 2011, 12                       
 
 
959 
Figure 8A depicts the CoMSIA steric contour map of the optimal QSAR model. A small green 
contour located on the outer side of C4’ position of ring C (shown in Figure 6C) represents regions 
where bulky groups can increase activity. In addition, another sterically favorable green contour, near 
the C2’ position of ring C, suggests that maybe substituents larger than methyl in this region is good 
for increasing the activity; therefore, reasonable structural modifications can be carried out to improve 
the activity and selectivity of Hsp90 inhibitors. The medium sized yellow contour localizes at the 
linker area between ring B and ring C indicating bulkier groups are unfavored at this position; for 
example, compounds 6 and 8 have bulkier linker (-SO2-, -COOCH2-) in this region which also have 
lower inhibitory activity than compound 19.  
The CoMSIA electrostatic contour map is presented in Figure 8B. The red contour overlapping the  
-COOCH3 group of compound 19 means that this group is favorable in this region and will lead to 
enhanced activity. The large blue contour encompasses ring A and the linker between ring B and ring 
C,  denotes  the  region  where  electropositive  groups  are  preferred  in  this  region;  for  example,  the 
activity of compounds 11 and 12 with the Cl
− and CH3O
− are less potent than compounds 14 which 
possesses H- at this position.  
The hydrophobic contour map of a CoMSIA model is shown in Figure 8C. The large yellow region 
at the C5 position of ring A stresses that hydrophobic substitutions will increase the inhibitor affinity. 
Due to another small yellow contour at the C2’ position of ring C, because of hydrophobic -CH3 
substituent at C2’ position, compound 19 displays high activity; whereas for the weak compounds, 9–15, 
no such substituent is present. Besides, at C4’ position of ring C, there is a large white contour, 
suggesting that hydrophilic groups in this area are favorable for inhibitory activity. 
Figure 8D shows the CoMSIA H-bond donor contour map. For this class of inhibitors, there are 
indeed less H-bond donor groups, therefore, the contour map here is mainly used for considering further 
modification of these compounds. A medium sized and a small cyan contour, around ring A, suggests 
that H-bond donor substituents are favorable for activity. However, at C5 and C3 position of ring A, 
there are chlorine and hydrogen which indicate that incorporation of H-bond donor groups at these two 
positions may improve the inhibitory activity. One small H-bond donor unfavorable purple contour, 
which is encompassed by the cyan contour, suggests the C atom in this area is very important to the 
inhibitory activity. That is, modification on ring C may be useful and a requirement to increase activity. 
3.4. Docking Analysis and Comparison with 3D Contour Maps  
Other than ligand-based 3D-QSAR analysis, we also performed receptor-based 3D-QSAR studies, 
which not only provides the natural interaction between the ligands and the receptor, but also applies 
for 3D-QSAR studies. In order to ensure the validity of docking calculations and of the conditions and 
parameters of docking, the ligands were flexibly redocked to the binding site of Hsp90 protein and the 
optimum docking conformations as the most probable binding conformation corresponding with the 
lowest energy score. The low RMSD values for the three different classes of inhibitors are 0.17 Å, 
0.05 Å and 0.02 Å, respectively. This means that the docking procedure is reliable and will reproduce 
the receptor bound conformation of other molecules in the dataset.  Int. J. Mol. Sci. 2011, 12                       
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Lastly, we analyzed whether the docking scores can be correlated to the biological data of the 
inhibitors. At the same time, we tried to compare the docking results with the 3D contour maps we 
analyzed above. 
3.4.1. BT 
The binding mode of the most active compound, 17 shown in Figure 9A, is taken as an example for 
analysis.  The  ligand-receptor  interaction  results  show  that  Met98,  Ile96,  Ala55,  Thr184,  Asp93, 
Asn51, Phe138, Tyr139, Leu107, Trp162 are the important residues at the active site and are the main 
contributors to the ligand and receptor interaction. The amide oxygen at the para position of benzamide 
ring forms hydrogen bond with OH of Thr184 (-O· · · HO, 1.95 Å, 130.2° ). The oxygen substituent of 
carbazol acts as an acceptor to form H-bond with OH of Tyr139 (-O· · · HO, 2.51 Å, 114.6° ). Another  
H-bond formed between the amino hydrogen at the para position of benzamide and the oxygen atom of 
Asp93 (-O· · · HN, 2.04 Å, 156° ). These results coincide with the previously quoted paper [32]. Residues 
Ala55,  Ile96,  Met98  formed  hydrophobic  contacts  with  the  ligands  which  are  favorable  for  the 
inhibitory activity. From Figure 9A, we can see the propylene substituent partially extended outside 
the binding pocket, as well as, the steric contour map (shown in Figure 5A) had a green contour at this 
position. On the other hand, the carbazol group forms π-π bond with Phe 138 which further enhanced 
the interaction between the ligand and the receptor. 
3.4.2. AT 
Compound  24  was  selected  as  a  reference  to  analyze  the  binding  mode  of  docking  shown  in. 
Figure 9B  From  the  map,  we  can  see  that  the  -OH  group  at  C4  position  of  benzamide  acts  as  a  
H-bond donor to form hydrogen bond with oxygen atom of carboxyl of Asp93 (-O· · · HO, 2.09 Å, 
145.7° ), which matched well with the H-bond donor contour depicted in Figure 7C. There is a large 
cyan contour around C4 position of benzamide which indicates that H-bond donor groups in this area 
are  favorable  for  the  inhibitory  activity.  One  hydrophobic  pocket  composed  of  residues  Leu48, 
Leu107, Val150, Va186, and the steric contour map with a green contour at C5 position of benzamide, 
suggests that bulky substituents in this area can increase the activity. However, large bulky substituents 
will lead to steric clash with these hydrophobic amino acids in this area, and would result in decreasing 
activity. Therefore, it is not benefitial to introduce too large groups to this position. At the same time, a 
group of hydrophilic amino acid Asp102, Lys58, Asn48 around C5’ position of isoindoline suggests 
that this area can hold bulky substituents, which coincides with the steric contour map depicted in 
Figure 7A. At the docking map, the subtituent at this position partially extended outside the binding 
pocket, which further indicates that bulky groups are favorable in this area for the inhibitory activity. 
The electropositive favorable blue contour at the C5 position of benzamide ring is surrounded by 
Thr184,  Asp93,  Asn51,  which  can  validate  the  3D  contour  map  analysis  that  the  activity  will  be 
enhanced by introducing electropositive groups at this position. In addition, another blue contour at 
C5’ position of isoindoline indicates electropositive substituents are favorable, which is consistent with 
the docking result whereby it favorably interacted with the backbone -NH of Asn106 and the -OH 
of Asp102. 
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3.4.3. DA 
Figure 9C shows the result of the docking study with compound 19 as a template. Compound 19 
forms a hydrogen bond between the oxygen atom of the -COO group at 4’ position of ring C and 
hydrogen atom of -NH group of Asn51 (-O· · · HN, 1.97 Å, 142.4° ). At the same time, the carbonyl 
oxygen atom at the linker, between ring A and ring B, forms hydrogen bond with the hydrogen atom of 
-OH group of Thr184 (-O· · · HO, 1.87 Å, 154° ). In addition, the third hydrogen bond forms between 
hydrogen atom of -OH group which is at C2 position of ring A and the oxygen atom of the -COO 
group of Asp93 (-O· · · HO, 2.00 Å, 114.4° ). This is consistent with the H-bond donor contour map 
(Figure 8D). The cyan contour around the C2 position of ring A suggests this is a H-bond donor 
favorable region. All of the hydrogen bonds described above are the same as those described in the 
original paper [34]. Figure 9C displays the methyl substituent at C2’ position of ring C embedded into 
a relatively large pocket composed of Val136, Gly135, Asn106. From the docking results, we can see 
that there is large free space in this pocket, suggesting that there is sufficient room for introducing 
bulky substituents, which is also validated by a sterically favorable green contour at this position seen 
in  the  CoMSIA  model.  The  hydrophilic  favorable  white  contour  at  the  C2’  position  of  ring  C  is 
enclosed  by  Asn106,  Asn51  and  Gly137,  which  explains  the  increased  activity  after  introducing 
hydrophilic groups in this area. The C2’ position of ring C is surrounded by carbonyl group of Asp54 
and Ser50 suggesting that electropositive substituents in this area are favorable for a binding activity of 
a ligand, correlating well with the analysis of the electrostatic contour map of the CoMSIA model 
which has a blue contour at this position. The red contour (Figure 8B) at the C4’ position of ring C 
suggests  an  electronegative  favorable  region,  corroborated  by  introducing  suitable  electronegative 
groups which would have a favorable interaction with the backbone NH of Phe138 and Asn51.  
That is, the results of the docking studies and 3D-QSAR can complement and validate each other, 
indicating that the 3D-QSAR model which we developed is reasonable and can offer constructive 
suggestions to the further rectification and modification of inhibitors of Hsp90. 
Figure 9. The enlargement for the structure of the binding site with substrates which are 
displayed in ball and sticks, H-bonds are shown as dotted green lines, and the nonpolar 
hydrogens were removed for clarity. (A) Docked conformation derived for compound 17 in 
complex  to  the  active  site  of  Hsp90  enzyme;  (B)  Docked  conformation  derived  for 
compound 24 with the binding site of Hsp90; (C) The docking structure of compound 19 
with the allosteric binding site of Hsp90 enzyme. 
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3.5. Comparison of Binding Modes for Each Class 
From the docking results, we can  compare  the inhibitory activity of the  three  series  of Hsp90 
inhibitors in order to better understand the variations in biological activities. According to the docking 
study, for BT, it mainly formed three hydrogen bonds between compound 17 and Thr184 (-O· · · HO, 
1.95Å, 130.2° ), Tyr139 (-O· · · HO, 2.51 Å, 114.6° ) and Asp93 (-O· · · HN, 2.04 Å, 156° ) of the receptor 
(Figure 9A). Additionally, for AT, only one hydrogen bond formed during the docking procedure. 
Asp93 (-O· · · HO, 2.09 Å, 145.7° ) served as the hydrogen bond donor to form hydrogen bond with 
compound  24  (Figure  9B).  As  for  the  class  of  DA,  three  hydrogen  bonds  were  formed.  From 
Figure 9C, we can see that Thr184 (-O· · · HO, 1.87 Å, 154° ), Asn51 (-O· · · HN, 1.97 Å, 142.4° ) and  
Asp93 (-O· · · HO, 2.00 Å, 114.4° ) were involved in the hydrogen bonding contacts with compound 19. 
From the docking study, we can simply conclude that the three series of Hsp90 inhibitors all involve 
one common active amino acid residue Asp93 (see Figure 10). On the other hand, BT and DA all form 
three hydrogen bonds which are more than the AT. Thus, we can assume that the activities of BT and 
DA are higher than AT. On the other hand, due to the fact that the docking analysis in this work 
eliminates the effect of environment, we do not consider waters which can form hydrogen bonds with 
inhibitors to enhance its stability and inhibitory activity. Therefore, it needs further analysis to validate 
the docking results. 
Figure 10. Docked conformations derived from compounds 17, 24, 19 with the binding 
site of Hsp90 protein; Hydrogen bonds are shown by broken lines; Compounds 17, 24, 19 
are shown in A, B and C, respectively as a reference, and are depicted in different colors: 
cyan, blue and orange. Thr184, Asp93, Tyr139, Asn51, as the significant residues, are 
colored by atom type (C, yellow; N, blue; H, white; O, red). 
 
3.6. Molecular Dynamics Simulations 
When predicting the binding orientation of ligand candidates to the binding site, docking analysis 
can provide a starting point for further calculations for the purpose of predicting the binding affinity of 
the molecules and to evaluate the stability of the predicted interactions involved in binding. In turn, 
MD simulations were undertaken to consider the impacts of the receptor flexibility and the effects of 
water solvation on the complex. 
The three docked complex structures of 3D0B with ligand 17 (the most potent compound of BT), 
2XJG with ligand 24 (the most potent compound of AT), 3K97 with ligand 19 (the most potent ligand 
of DA) have done a 5 ns simulation. The simulations were performed to obtain a dynamical picture of Int. J. Mol. Sci. 2011, 12                       
 
 
963 
the conformational change in the MD simulations; the main purpose is to explore the conformational 
alterations that take place in the ligand and the receptor. 
3.6.1. BT 
The RMSD of 3D0B complex is shown in Figure 11A. The RMSDs of the trajectory with respect to 
their initial structure range from 1.2 to 1.5 Å. After 2 ns, the RMSDs of the complex reach about 
1.4 Å, and retain this value throughout the simulation. A superposition of the stable structure in all the 
MD simulations (coming after 2 ns) and the initial docked structure is shown in Figure 11B, C. After 
MD simulation, we analyzed interactions between compound 17 and the receptor in order to explore 
the similarity and difference between the results of docking and MD simulation. From the average 
structure extracted from the MD simulation, we can see that it mainly forms four hydrogen bonds 
(shown in Figure 12A). A proper H-bond (1.55 Å) is built between the oxygen substituent of carbazol 
and Tyr139; the docked model of the complex also formed hydrogen bond with Tyr139 with a distance 
of 2.51 Å, which is bigger than the former. The other two hydrogen bonds formed between the two 
amino  hydrogens  at  the  para  position  of  benzamide  ring  and  Asp93  (-O· · · HN,  2.61  Å,  99.6° ),  
(-O· · · HN, 2.84 Å, 106.1° ). For the docking result, only one hydrogen bond was formed in this position. 
In addition, the amide oxygen atom at the para position of benzamide ring acts as hydrogen acceptor to 
form H-bond with the amino group N atom of Ala55 (-O· · · HN, 3.52 Å, 100.4° ). At the same time, it 
also produces π-π bond between the carbazol and Phe138 to enhance its stable conformation and 
binding activity.  
Figure 11. (A) Plot of the root-mean-square deviation (RMSD) of docked complex versus 
the MD simulation time in the MD-simulated structures; (B), (C) View of superimposed 
backbone atoms of the lowest energy structure of the MD simulation (cyan) and the initial 
structure  (green)  for  compound  17-3D0B  complex.  Compound  17  is  represented  as  
carbon-chain  in  green  for  the  initial  complex  and  carbon-chain  in  cyan  for  the  lowest 
energy complex. 
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Figure 12. Plot of the MD-simulated structures of the binding site with ligand. H-bonds are 
shown as dotted black lines; Active site amino acid residues are represented as sticks; the 
inhibitors are shown as stick and ball model. (A) Compound 17 in complex to the active 
site of Hsp90 enzyme; (B) Compound 24 with the binding site of Hsp90; (C) Compound 19 
with the allosteric binding site of Hsp90 enzyme. 
 
3.6.2. AT 
As for this class of inhibitors, the RMSDs of the trajectory with respect to their initial structure 
ranging from 1.3 to 2.2 Å are depicted in Figure 13A. A superposition of the average structure of 
ensemble  and  the  docked  structure  is  shown  in  Figure  13B.  Figure  12B  shows  the  conformation 
derived for compound 24 with the allosteric binding site of 2XJG, in which five hydrogen bonds were 
produced which is more than the docking process. The hydroxyl group H atom at C4 position of 
benzamide forms H-bond with the oxygen atom of carboxyl of Asp93 (-O· · · HO, 1.35 Å, 165.1° ) as 
well as the docking result. However, the hydrogen bond formed by the docking process with a distance 
of 2.09 Å. The other H-bonds form between the hydroxyl group H atom at C4 position of benzamide 
and the oxygen atom of Ser52 (-O· · · HO, 1.66 Å, 139.9° ); the oxygen atom of carboxyl between the 
benzamide  ring  and  the  isoindoline  ring  forms  hydrogen  bond  with  the  Asn51  (-O· · · HN,  1.74  Å, 
113.5° ).  The  oxygen  atom  of  the  substituent  at  the  C5’  position  of  isoindoline  forms  two  
H-bonds with the backbone NH2 of Lys58 (-O· · · HN, 2.97 Å, 80.2° ) and (-O· · · HN, 2.36 Å, 116.9° ). 
3.6.3. DA 
Figure 14A shows the RMSD values, the RMSDs of the trajectory with respect to their initial 
structure ranging from 1.4 to 2 Å for 3K97. After 2 ns, the RMSDs of the complex reach about 1.8 Å 
and retain these values throughout the simulation. This clearly indicates that the docked complexes can 
reach metastable conformation after 2 ns of simulation. Figure 14B, C represents the superimposed 
backbone atoms of the lowest energy structure of the MD simulation and the initial structure.  By 
combining Figure 14B, C and Figure 12C, we attempt to analyze the differences between the structure 
extracted from MD simulations and the docked model of the complex. The docked complex structure 
of 3K97 with ligand 19 was further used for molecular dynamics to obtain a dynamical picture of the 
conformational changes. Figure 12C shows that the ligand core is anchored in the binding site via four 
H-bonds. The hydrogen atom of -OH group at C2 position of ring A interacts through H-bonding with 
the backbone -COO of Asp93 (-O· · · HO, 1.14 Å, 133.4° ), and the same H-bond is formed for the 
docking result, but with a distance of 2.00 Å. In addition, the carbonyl oxygen atom at the linker Int. J. Mol. Sci. 2011, 12                       
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between ring A and ring B form two hydrogen bonds with NH group of Gly97 (-O· · · HN, 1.66 Å, 
167.2° ) and Ile96 (-O· · · HN, 1.89 Å, 137.6° ). Also the oxygen atom of the COO- group at C4’ position 
of ring C forms H-bond with NH group of Phe138 (-O· · · HN, 1.94 Å, 165.5° ). All these three hydrogen 
bonds are different from the docking results. 
The analysis described above suggest that there is no significant differences between the stable 
structure extracted from MD simulations and the docked model of the complex, which indicates that 
the docking model is rational and valid. But there are also some differences between them, such as the 
number and length of hydrogen bonds and the main amino acids involved in forming hydrogen bonds. 
To sum it up, the conformations obtained after molecular dynamics are more stable than the docked 
conformations. This coincides with the QSAR results derived from the receptor-based method, which 
have poorer prediction than the ligand-based method. This also can be explained by the fact that the 
docking method itself has some shortcomings and does not consider the impact of solvents which are 
not explicitly treated. However, MD simulation is performed in a more realistic environment, and 
much  closer  to  physiological  conditions.  In  addition,  compared  with  the  docking  analysis,  the 
corresponding binding mode from MD simulation has better correlation with the 3D-QSAR analysis. 
Figure 13. (A) Plot of the root-mean-square deviation (RMSD) of docked complex versus 
the MD simulation time in the MD-simulated structures; (B), (C) View of superimposed 
backbone atoms of the lowest energy structure of the MD simulation (cyan) and the initial 
structure  (green)  for  compound  24-2XJG  complex.  Compound  24  is  represented  as  
carbon-chain  in  green  for  the  initial  complex  and  carbon-chain  in  cyan  for  the  lowest 
energy complex. 
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Figure 14. (A) Plot of the root-mean-square deviation (RMSD) of docked complex versus 
the MD simulation time in the MD-simulated structures; (B), (C) View of superimposed 
backbone atoms of the lowest energy structure of the MD simulation (cyan) and the initial 
structure  (green)  for  compound  19-3K97  complex.  Compound  19  is  represented  as  
carbon-chain  in  green  for  the  initial  complex  and  carbon-chain  in  cyan  for  the  lowest 
energy complex. 
 
4. Conclusions 
3D-QSAR  studies  on  three  kinds  of  Hsp90  inhibitors  using  CoMFA  and  CoMSIA  based  on  
ligand- and receptor-based methods have led to the identification of important structural features of 
steric, electrostatic, hydrophobic and H-bond donor interactions between the receptor and its ligand. 
The obtained QSAR models are reliable, evidenced by the high r
2
cv values and small standard errors, 
and the 3D contour maps are also well correlated with docking models.  
For BT series, the CoMFA model yields relatively better prediction than the CoMSIA one, which 
reveals the importance of the steric effect, making a contribution of 82.5% to the model. The results 
indicate that -R1 group was very important for the inhibitory activity. Docking studies reveal that the 
amino hydrogen and the oxygen atom at the para position of benzamide, and the oxygen substituent of 
carbazol plays a main contribution to enhance the activity. 
For AT derivatives, the optimal CoMSIA model shows that the bulky electropositive groups at C5 
position of benzamide and electropositive; H-bond donor groups at positions C3, C4 of benzamide had 
a positive effect on the inhibitory activity. The docking study reveals that substituent at C5 position of 
benzamide can bind to a hydrophobic pocket, while the -OH group at C2 position of benzamide forms 
hydrogen bond with the backbone of Asp93.  
For DA analogs, the contour map showed that the substituents at C2 and C4 position of ring C had a 
great  impact  on  the  overall  inhibitory  activities,  which  is  consistent  with  the  docking  results. 
Electropositive substituent at C2 position is surrounded by Asp54 and Ser50, which was favorable for Int. J. Mol. Sci. 2011, 12                       
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a binding activity. In addition, electronegative substituent at C4 position has a good interaction with 
the  backbone  NH  of  Phe138  and  Asn51.  It  also  formed  hydrogen  bond  with  hydrogen  atom  of  
-NH group of Asn51. In summary, good consistency between the 3D-QSAR, the docking and MD 
modeling results indicates the robustness of the 3D-QSAR models, which can serve as a basis for 
modification and design of novel anticancer compounds with enhanced activities. 
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